Moomoo AI 已提取核心信息
Intelligent Bio Solutions Inc. (INBS), a medical technology company, announced a significant year-over-year revenue increase in its fiscal second quarter and six-month financial results ending December 31, 2023. The company reported a 114% revenue increase for the quarter and a 337% increase for the six-month period, attributed to the acquisition of Intelligent Fingerprinting Ltd and growth in the Asia Pacific business. Despite the revenue growth, INBS experienced a net loss increase from $1.63 million to $4.39 million for the six months compared to the previous year, primarily due to the combined results of operations post-acquisition. The company also highlighted its expansion into the New Zealand market and increased market share in existing regions. Notably, INBS's laboratory partner received accreditation from the National Association of Testing Authorities for its fingerprint confirmatory drug testing procedure. The company's President and CEO, Harry Simeonidis, expressed optimism about the growth trajectory and the potential for further expansion in the Asia-Pacific region. INBS ended the quarter with cash and cash equivalents of approximately $1.12 million.
Intelligent Bio Solutions Inc. (INBS), a medical technology company, announced a significant year-over-year revenue increase in its fiscal second quarter and six-month financial results ending December 31, 2023. The company reported a 114% revenue increase for the quarter and a 337% increase for the six-month period, attributed to the acquisition of Intelligent Fingerprinting Ltd and growth in the Asia Pacific business. Despite the revenue growth, INBS experienced a net loss increase from $1.63 million to $4.39 million for the six months compared to the previous year, primarily due to the combined results of operations post-acquisition. The company also highlighted its expansion into the New Zealand market and increased market share in existing regions. Notably, INBS's laboratory partner received accreditation from the National Association of Testing Authorities for its fingerprint confirmatory drug testing procedure. The company's President and CEO, Harry Simeonidis, expressed optimism about the growth trajectory and the potential for further expansion in the Asia-Pacific region. INBS ended the quarter with cash and cash equivalents of approximately $1.12 million.
医疗技术公司智能生物解决方案公司（INBS）宣布，其第二财季收入同比大幅增长，截至2023年12月31日的六个月财务业绩。该公司报告称，本季度收入增长114％，六个月内增长337％，这归因于对智能指纹有限公司的收购以及亚太业务的增长。尽管收入增长，但与去年相比，INBS六个月的净亏损从163万美元增加到439万美元，这主要是由于收购后的综合经营业绩。该公司还强调了其向新西兰市场的扩张以及在现有地区的市场份额的增加。值得注意的是，INBS的实验室合作伙伴因其指纹确认药物测试程序获得了全国测试机构协会的认证。该公司总裁兼首席执行官哈里·西蒙尼迪斯对亚太地区的增长轨迹和进一步扩张的潜力表示乐观。INBS在本季度末的现金及现金等价物约为112万美元。
医疗技术公司智能生物解决方案公司（INBS）宣布，其第二财季收入同比大幅增长，截至2023年12月31日的六个月财务业绩。该公司报告称，本季度收入增长114％，六个月内增长337％，这归因于对智能指纹有限公司的收购以及亚太业务的增长。尽管收入增长，但与去年相比，INBS六个月的净亏损从163万美元增加到439万美元，这主要是由于收购后的综合经营业绩。该公司还强调了其向新西兰市场的扩张以及在现有地区的市场份额的增加。值得注意的是，INBS的实验室合作伙伴因其指纹确认药物测试程序获得了全国测试机构协会的认证。该公司总裁兼首席执行官哈里·西蒙尼迪斯对亚太地区的增长轨迹和进一步扩张的潜力表示乐观。INBS在本季度末的现金及现金等价物约为112万美元。
有用
没用